MIT and Harvard Build “Invisible” Immune Cells That Obliterate Cancer

MIT and Harvard scientists have created engineered CAR-NK cells that can hide from the immune system and more effectively ...
Lupus Foundation of America

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...
Frontiers

The half-century odyssey of regulatory B cells: from Breg discovery to emerging frontiers

For half a century, the quiet work of a specialized immunosuppressive B cell subset has been slowly unveiled, revealing its profound impact on immune balance. This review provides a comprehensive ...
precisionmedicineonline

Lion TCR to Launch Phase I/II Trial of Hepatitis B TCR T-Cell Therapy in US

NEW YORK – The US Food and Drug Administration has granted Singapore-based Lion TCR permission to begin a Phase Ib/II trial for a T-cell receptor (TCR) T-cell therapy, LioCyx-M004, in patients with ...